Treatment of Psoriasiform Dermatitis Using Systemic Biologics and Small Molecules: An Evidence-Based Review

Abstract

Keywords

biologics small molecules JAK inhibitors psoriasiform dermatitis

Get full access to this article

View all access options for this article.

References

Mao

Jia

, et al. Case report. Treatment of psoriasiform dermatitis in patients with malignancy. Front Med. 2024;11:Article 1363405. doi:10.3389/fmed.2024.1363405

Megna

Caiazzo

Parisi

, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?. Clin Exp Dermatol. 2022;47(5):918-925. doi:10.1111/ced.15052

Zhou

Xiong

, et al. A case of paradoxical reactions to biologic therapy for psoriasis. Clin Cosmet Investig Dermatol. 2023;16:1493-1497. doi:10.2147/CCID.S412520

Al-Janabi

Foulkes

Griffiths

CEM

Warren

RB.

Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clin Exp Dermatol. 2022;47(6):1174-1178. doi:10.1111/ced.15130

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.03 MB

0.08 MB

0.02 MB